ReviewOphthalmology and therapy2026
GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
Review in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become a recurring topic in ophthalmology, yet most reviews emphasize posterior segment and neuro-ophthalmic disease while giving comparatively little attention to the ocular surface. In this review, we frame the relevant target not as isolated anterior structures but as a proposed metabolic surface unit composed of the lacrimal gland, tear film, conjunctiva, meibomian glands, corneal epithelium, corneal nerves, and the periocular tissues that support lid-globe function, and we argue that current evidence is best understood as restoration versus remodeling. Preclinical work provides the clearest biologic rationale: liraglutide studies have reported reduced lacrimal gland inflammation and fibrosis, and improved tear secretion, corneal epithelial migration, and nerve regeneration, while a semaglutide study in aged mice suggests lacrimal structural rescue through attenuation of senescence-associated inflammatory, oxidative, and fibrotic programs. Human evidence remains limited and largely observational, with retrospective diabetic cohorts showing lower rates of dry eye disease and superficial keratitis and a small clinical study showing better Schirmer testing and tear breakup time in GLP-1RA users. At the same time, emerging oculoplastic and imaging studies, particularly from obesity and weight loss populations, suggest periocular volume loss, brow descent, and dermatochalasis which may alter lid support, blink mechanics, and tear distribution. For anterior segment clinicians, the practical implication is that GLP-1RA exposure should prompt phenotype-based assessment of both ocular surface status and periocular geometry, although these recommendations remain expert extrapolations rather than guideline-level evidence. Current data are therefore consistent with a dual thesis: GLP-1RAs may be associated with biologic restoration at the lacrimal-corneal-neural axis and with structural remodeling of the periocular scaffold, although direct mechanistic support is presently stronger for the former than for the latter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.